Last checked at 22 Jul 2020 07:00
22 July, 2020
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Grant of options
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), announces that yesterday, 21 July 2020, the Board approved the issue of 11,412,500 share options to 39 existing employees and the Executive Directors under the Company's 2003 Share Option Scheme (the "EMI Share Scheme").
Employee Share Option Scheme
Incorporated into the EMI Share Scheme, the Board has approved the issue of 4,000,000 share options to Andy Mears, Chief Executive, and 1,000,000 to David Moorhouse, Group Finance Director. The exercise price is 1.325 pence per share option, the closing price on 21 July 2020. These share options may ordinarily be exercised between January 2021 and July 2030 and for the Executive Directors are subject to performance conditions which are based on achieving certain specified adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) targets.
Confirmation of Directors' interests in share options
Following the grant of EMI options above, the options held by Directors are shown below:
Executive Director 2011 Executive Share Scheme 2003 EMI Share Scheme Total
Number Number Number
Andy Mears 2,387,500 14,000,000 16,387,500
David Moorhouse - 1,000,000 1,000,000
Nigel Keen, Deltex Medical's Chairman, commented:
"Having come through the lockdown period, and in the expectation of the resumption of elective surgery, the Board wanted to show its appreciation to our employees and to involve them in the future success of the Company by granting these share options."
For further information, please contact:
Deltex Medical Group plc | 01243 774 837 |
Nigel Keen, Chairman | investorinfo@Deltexmedical.com |
Andy Mears, Chief Executive |
|
David Moorhouse, Group Finance Director |
|
|
|
Arden Partners plc | 020 7614 5900 |
Ciaran Walsh Dan Gee-Summons |
|
|
|
Joint Broker |
|
Turner Pope Investments (TPI) Ltd | 0203 657 0050 |
Andy Thacker Zoe Alexander | info@turnerpope.com |
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | a. Andy Mears (Chief Executive) b. David Moorhouse (Group Finance Director)
|
2 | Reason for the notification | |
a) | Position/status | See 1 a) above |
b)
| Initial notification /Amendment | Initial notification |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Deltex Medical Group plc |
b) | LEI | 213800XN34P6LI8J6M39 |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a)
| Description of the financial instrument, type of instrument Identification code | Issue of share options
Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583
|
b) | Nature of the transaction | Issue of options |
c) | Price(s) and volume(s) | Issue of share options a. 4,000,000 b. 1,000,000
|
d) | Aggregated information - Aggregated volume - Price |
5,000,000 Exercisable at 1.325 pence |
e) | Date of the transaction | 21 July 2020 |
f) | Place of the transaction | Outside a trading venue |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia protocols for surgical patients, as well as treating ventilated intensive care patients, including ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's clinical condition as well as the skill and expertise of the user. Doing this will enable the Group to partner with healthcare providers to support modern haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and via agreements with approximately 40 distributors overseas.